TIEKF yields 1.95% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 7
Combined, TIEKF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TIEKF + JNJ for your $10,000?
TIE Kinetix N.V. develops, distributes, and sells software and services in the Netherlands, the United States, Germany, and France. The company offers digital supply chain solutions; and electronic document exchange solutions, such as electronic data interchange (EDI)-2-FLOW, PDF-2-FLOW, and PORTAL-2-FLOW, as well as E-Archiving. It also provides software as a service solution for exchanging business documents to companies, governmental institutions, and trading partners and suppliers, as well as artificial intelligence-powered onboarding services. In addition, the company offers AP automation solutions for buyers and suppliers to engage in smart business exchanges; pre-built connectors and standardized API integrations to connect to ERP or other systems; compliance solutions; value added network services, which enables trading partners to communicate and exchange business documents in various formats real-time using various communication protocols; electronic invoicing solutions; and consultancy services. Further, it provides FLOW Partner Automation platform that combines supply chain integration solutions, such as EDI/XML, PDF conversion, and supplier portal, as well as analytics data and dashboards for users. The company offers its solutions to business services, industry and home improvement, telecom, banking and insurance, food industry and food retail, non-food, consumer electronics, transport and logistics, office supplies, automotive, medical, and others markets directly, as well as through a network of distribution partners. TIE Kinetix N.V. was founded in 1987 and is headquartered in Breukelen, the Netherlands.
Full TIEKF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.